Cover Image
市場調查報告書

小動物成像 (In-vivo) 的全球市場 (技術,用途,各地區) - 產業分析與預測 (2013∼2020年)

Global Small Animal Imaging (In-Vivo) Market (Technology, Applications and Geography) - Industry Analysis and Forecast, 2013 - 2020

出版商 Allied Market Research 商品編碼 329503
出版日期 內容資訊 英文 162 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
小動物成像 (In-vivo) 的全球市場 (技術,用途,各地區) - 產業分析與預測 (2013∼2020年) Global Small Animal Imaging (In-Vivo) Market (Technology, Applications and Geography) - Industry Analysis and Forecast, 2013 - 2020
出版日期: 2015年02月15日 內容資訊: 英文 162 Pages
簡介

全球小動物成像(In-vivo)市場預測到2020年前將達到21億美金。製藥公司及臨床研究機關的增加、前臨床研究上in-vivo成像應用的擴大、即時資料儲存和高解析度模式的引進等,都是推動市場成長的要素。

本報告提供全球小動物成像 (In-vivo) 市場相關調查,提供您市場現狀與2020年前的發展預測,並彙整競爭趨勢,參與企業的SWOT分析,及簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 靜脈注射免疫球蛋白概要
  • 技術進步:in-vivo影像的多重模式
  • 對投資者而言的利益標準和新興經濟
  • 主要調查結果
  • 政府的法規與給付
  • 波特五力分析
  • 價值鏈分析
  • 專利分析
  • 主要加入企業的定位 (2013年)
  • 市場趨勢
    • 促進成長要素
    • 阻礙要素
    • 機會

第4章 各技術全球小動物成像 (In-vivo) 市場

  • 微核磁共振攝影影像
  • 光學影像
  • 核子醫學攝影
  • 其他模式

第5章 各用途全球小動物成像 (In-vivo) 市場

  • 治療反應的監測
  • 生物內分佈,藥物/標的參與度的決定
  • 癌症細胞檢測
  • 生物標記
  • 長期的研究
  • 表觀遺傳學

第6章 各地區全球小動物成像 (In-vivo) 市場:2013年與2020年

  • 北美
  • 歐洲
  • 亞太地區
  • 南美·中東·非洲

第7章 企業簡介

  • Thermo Fisher Scientific
  • Siemens AG
  • Mediso Medical Imaging Systems
  • Life Technologies Corporation
  • Promega Corporation
  • Miltenyi Biotech GmbH
  • Bruker Corporation
  • FUJIFILM horutingusu株式會社
  • PerkinElmer, Inc.
  • Aspect Imaging Ltd
  • BDI Pharma Inc.
  • Bayer Healthcare

圖表

目錄
Product Code: DI 15474

Title: Global Small Animal Imaging (In-Vivo) Market by Technology (Micro-MRI, Optical Imaging, Nuclear Imaging) and Applications (Epigenetics, Biomarkers, Longitudinal Studies, Biodistribution Studies, Cancer Cell Tetection) - Global Opportunity Analysis and Industry Forecast, 2013 - 2020.

Imaging modalities emerged as a preferred option for the clinical industry, especially in preclinical studies. Many of the imaging technologies have been translated into micro level tools that include micro MRI, micro CT and micro PET. Apart from these technologies, micro ultrasound imaging, micro-magnetic resonance imaging (MRI), optical Imaging such as bioluminescence and fluorescence imaging, and multimodal imaging technologies have gained traction in the market. Rising number of the pre-clinical research, increasing investments by the CROs in the research activities, growing applications of multi-functional pre-clinical imaging and technological advancements such as high resolution multimodality MRI are the few factors impacting the global market positively. However, the stringent regulatory impositions coupled with inadequate reimbursement scenario would restrain the market growth to a certain extent. Despite of the aforementioned market restraints, commercialization of cost-efficient devices would ease the negative influence of restraints and fuel the market growth, primarily across the developing regions.

The market for small animal imaging (In-Vivo) is expected to reach at $2.1 billion by 2020. Rising number of Pharmaceutical companies and clinical research organizations, increasing applications of in-vivo imaging in pre-clinical research, real time data storage and high-resolution modalities, are the key growth factors of the market. Inadequate infrastructure provisions for research facilities, advanced instruments and the lack of skilled research personnel in emerging economies along with the requirement of high-end devices are likely to be the major restraints of small animal imaging (in-vivo) market. Going forward, the global clinical research initiatives, along with the development in technologies associated with pre-clinical trials will provide the platform for growth.

North America, dominates the market amongst all geographies owing to adoption of advanced technologies, healthcare awareness and favorable reimbursement policies. Geographically, about ~35 of the small animal imaging (in-vivo) market share is held by the North America owing to the heavy investments and affordability of advanced small animal in-vivo imaging devices in pre-clinical research. On the other hand, Asia-Pacific market would grow at the promising CAGR of 11.5% over the forecast period. Such high growth rate is majorly attributed towards untapped state of the market, hence would provide an opportunities for the small animal imaging devices manufacturers.

KEY BENEFITS

  • The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on
  • The report helps in understanding the strategies adopted by various companies for gaining market share in the small animal imaging (in-vivo) market
  • The report provides comprehensive analysis of factors that drive and restrict the growth of the small animal imaging (in-vivo) market
  • Market conditions of small animal imaging (in-vivo) market across all geographic regions are comprehensively analyzed.
  • Competitive intelligence (of leading manufacturers) helps in understanding the competitive scenario across the geographies
  • SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies

MARKET SEGMENTATION

The small animal imaging (in-vivo) market is segmented by the technology, applications and geography.

SMALL ANIMAL IMAGING (IN-VIVO) MARKET BY TECHNOLOGY

  • Micro-Magnetic Resonance Imaging (Micro-MRI)
  • Optical Imaging (OI)
    • Bioluminescence Imaging
    • Cerenkov Luminescence Imaging
    • Fluorescence Imaging
  • Nuclear Imaging
    • Micro-Positron Emission Tomography (Micro-PET)
    • Micro-Single Photon Emission Computerized Tomography (Micro-SPECT)
  • Others
    • Micro-Ultrasound Imaging
    • Micro-Computerized Tomography (Micro-CT)

SMALL ANIMAL IMAGING (IN-VIVO) MARKET BY APPLICATIONS

  • Monitoring Drug Treatment Response
  • Biodistribution Studies
  • Cancer Cell Detection
  • Biomarkers
  • Longitudinal Studies
  • Epigenetics

MARKET BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Table of Contents

CHAPTER 1 - INTRODUCTION

  • 1.1. Key Benefits
  • 1.2. Key Market Segments
  • 1.3. Key Audiences
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2 - EXECUTIVE SUMMARY

  • 2.1. Market beyond what to expect by 2025($Million)
    • 2.1.1. Moderate growth scenario
    • 2.1.2. Rapid growth scenario
    • 2.1.3. Diminishing growth scenario

CHAPTER 3 - MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Technological Advancements: Multimodality In Vivo Imaging
    • 3.2.1. Multimodality Imaging
    • 3.2.2. Cloud Computing and Real Time Data Storage
  • 3.3. Emerging Economies as a beneficial criterion for investors
  • 3.4. Key Findings
    • 3.4.1. Top factors impacting for small animal imaging (In Vivo) market
    • 3.4.2. Top investment pockets for small animal imaging (In Vivo) market
    • 3.4.3. Top winning strategies for small animal imaging (In Vivo) market
  • 3.5. Government Regulations and reimbursement
    • 3.5.1. Regulations in United States
    • 3.5.2. Regulations in Europe
    • 3.5.3. Regulations in Asia Pacific
    • 3.5.4. Reimbursement Scenario
  • 3.6. Porter's Five Force Analysis
    • 3.6.1. Bargaining power of Suppliers (Lower)
    • 3.6.2. Bargaining power of buyers (High)
    • 3.6.3. Threats from substitute products (High)
    • 3.6.4. Threat from new entrants (Low)
    • 3.6.5. Moderate Industry rivalry
  • 3.7. Value chain analysis
  • 3.8. Patent Analysis
    • 3.8.1. Patent Analysis by type of patents
    • 3.8.2. Patent Analysis by Geography
  • 3.9. Key market player positioning (2013)
  • 3.10. Market dynamics
    • 3.10.1. Growth Drivers
      • 3.10.1.1. Increasing use of Multi functional pre clinical imaging
      • 3.10.1.2. rising investments from clinical research organizations for pre clinical studies
      • 3.10.1.3. rising number of pharmaceutical organizations and research institutions
      • 3.10.1.4. Technological innovations such as combination of high resolution mri with other imaging modalities future growth driver
    • 3.10.2. Restraints
      • 3.10.2.1. Stringent regulatory requirements
      • 3.10.2.2. Inadequate reimbursements a barrier in In vivo imaging devices adoption
      • 3.10.2.3. Accuracy and cost a hindrance in worldwide adpotion of small animal imaging techniques
    • 3.10.3. Opportunities
      • 3.10.3.1. Development of new high resolution in vivo imaging techniques
      • 3.10.3.2. Ultrasound contrast imaging techniques An Opportunity to improve efficiency in the pre clinical drug discovery and development process

CHAPTER 4 - GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET BY TECHNOLOGY

  • 4.1. Micro Magnetic Resonance Imaging
    • 4.1.1. Key market trends
    • 4.1.2. Key growth factors and opportunities
    • 4.1.3. Market size and forecast
  • 4.2. Optical Imaging
    • 4.2.1. Key market trends
    • 4.2.2. Key growth factors and opportunities
    • 4.2.3. Market size and forecast
    • 4.2.4. Bioluminescence Imaging
    • 4.2.5. Cerenkov Luminescence Imaging
    • 4.2.6. Fluorescence Imaging
  • 4.3. Nuclear Imaging
    • 4.3.1. Key market trends
    • 4.3.2. Key growth factors and opportunities
    • 4.3.3. Market size and forecast
    • 4.3.4. Micro Positron Emission Tomography (Micro PET)
    • 4.3.5. Micro Single Photon Emission Computerized Tomography (Micro SPECT)
  • 4.4. Other Imaging Modalities
    • 4.4.1. Micro Computerized Tomography Imaging
      • 4.4.1.1. Key market trends
      • 4.4.1.2. Key growth factors and opportunities
    • 4.4.2. Micro Ultrasound Imaging
      • 4.4.2.1. Key Market Trends
      • 4.4.2.2. Key Growth Factors and Opportunities
      • 4.4.2.3. Market size and forecast

CHAPTER 5 - GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET BY APPLICATION

  • 5.1. Monitoring Treatment Response
    • 5.1.1. Market Size and forecast
  • 5.2. Biodistribution, Determining Drug/Target Engagement
    • 5.2.1. Market Size and forecast
  • 5.3. Cancer cell detection
    • 5.3.1. Market Size and forecast
  • 5.4. Biomarkers
    • 5.4.1. Market Size and forecast
  • 5.5. Longitudinal studies
    • 5.5.1. Market Size and forecast
  • 5.6. Epigenetics
    • 5.6.1. Market Size and forecast

CHAPTER 6 - GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET BY GEOGRAPHY, 2013 2020, $MILLION

  • 6.1. North America
    • 6.1.1. Key Market Trends
    • 6.1.2. Key growth factors and opportunities
    • 6.1.3. Market size and forecast
  • 6.2. Europe
    • 6.2.1. Key market trends
    • 6.2.2. Future growth factors and opportunities
    • 6.2.3. Market size and forecast
  • 6.3. Asia Pacific
    • 6.3.1. Key market trends
    • 6.3.2. Key growth factors and opportunities
    • 6.3.3. Market size and forecast
  • 6.4. LAMEA
    • 6.4.1. Key market trends
    • 6.4.2. Future growth factors and opportunities
    • 6.4.3. Market size and forecast

CHAPTER 7 - COMPANY PROFILES

  • 7.1. Thermo Fisher Scientific
    • 7.1.1. Company overview
    • 7.1.2. Company snapshot
    • 7.1.3. Operating business segment overview
    • 7.1.4. Business performance
    • 7.1.5. Strategic moves and developments
    • 7.1.6. SWOT analysis
  • 7.2. Siemens AG
    • 7.2.1. Company overview
    • 7.2.2. Company snapshot
    • 7.2.3. Operating business segment overview
    • 7.2.4. Siemens AG Business Performance
    • 7.2.5. Strategic Moves And Developments
    • 7.2.6. SWOT analysis of Siemens AG
  • 7.3. Mediso Medical Imaging Systems
    • 7.3.1. Company profile
    • 7.3.2. Company snapshot
    • 7.3.3. Operating business segment overview
    • 7.3.4. Strategic moves and developments
    • 7.3.5. SWOT analysis
  • 7.4. Life Technologies Corporation
    • 7.4.1. Company profile
    • 7.4.2. Company snapshot
    • 7.4.3. Operating business segment overview
    • 7.4.4. Business performance
    • 7.4.5. Strategic moves and developments
    • 7.4.6. SWOT analysis of Life Technologies Corporation
  • 7.5. Promega Corporation
    • 7.5.1. Company profile
    • 7.5.2. Company snapshot
    • 7.5.3. Operating business segment overview
    • 7.5.4. Business performance
    • 7.5.5. Strategic Moves And Developments
    • 7.5.6. SWOT analysis of Promega Corporation
  • 7.6. Miltenyi Biotech GmbH
    • 7.6.1. Company profile
    • 7.6.2. Company snapshot
    • 7.6.3. Operating business segment overview
    • 7.6.4. Business Performance
    • 7.6.5. Strategic moves and developments
    • 7.6.6. SWOT analysis
  • 7.7. Bruker Corporation
    • 7.7.1. Company profile
    • 7.7.2. Company snapshot
    • 7.7.3. Operating business segment overview
    • 7.7.4. Business Performance of Bruker Corporation
    • 7.7.5. Strategic moves and developments
    • 7.7.6. SWOT analysis of Bruker Corporation
  • 7.8. FUJIFILM Holdings Corporation
    • 7.8.1. Company Profile
    • 7.8.2. Company snapshot
    • 7.8.3. Business Performance of FujiFilm Holding Corporation
    • 7.8.4. Business Performance of FujiFilm Holding Corporation:
    • 7.8.5. Strategic moves and developments
    • 7.8.6. SWOT Analysis of FujiFilm Holding Corporation
  • 7.9. PerkinElmer, Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Business Performance of PerkinElmer Inc.
    • 7.9.3. Business Performance of PerkinEmer Inc.:
    • 7.9.4. Strategic Moves and Development
    • 7.9.5. SWOT analysis of PerkinElmer Inc.
  • 7.10. Aspect Imaging Ltd.
    • 7.10.1. Company Overview
    • 7.10.2. Company snapshot
    • 7.10.3. Business Performance of Aspect Imaging Ltd.
    • 7.10.4. Strategic moves and developments
    • 7.10.5. SWOT analysis

List of Tables

  • TABLE 1: MODERATE GROWTH RATE SCENARIO OF SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2020-2025 ($MILLION)
  • TABLE 2: RAPID GROWTH RATE SCENARIO OF SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2020-2025 ($MILLION)
  • TABLE 3: DIMINISHING GROWTH RATE SCENARIO OF SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2020-2025 ($MILLION)
  • TABLE 4: PRODUCT LAUNCH AS A GROWTH STRATEGY BY THE KEY MARKET PLAYERS IN SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2011 2014
  • TABLE 5: EXPANSION AS A GROWTH STRATEGY BY THE KEY MARKET PLAYERS IN SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2012 2014
  • TABLE 6: ACQUISITION AS A GROWTH STRATEGY BY THE KEY MARKET PLAYERS IN SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2012 2014
  • TABLE 7: MEDICAL DEVICES CATEGORIES ACCORDING TO EUROPEAN COMMISSION
  • TABLE 8: SUMMARY FOR GENERAL PROPERTIES OF IMAGING MODALITIES
  • TABLE 9: GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET BY TECHNOLOGY, 2013 2020 ($MILLION)
  • TABLE 10: GLOBAL SMALL ANIMAL MICRO MRI IMAGING MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 11: GLOBAL SMALL ANIMAL OPTICAL IMAGING MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 12: COMPARISON OF BIOLUMINESCENT IMAGING REPORTER PROTEINS
  • TABLE 13: TECHNOLOGICAL FEATURES OF COMMERCIALLY AVAILABLE MICRO PET SCANNERS
  • TABLE 14: GLOBAL SMALL ANIMAL NUCLEAR IMAGING MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 15: GLOBAL SMALL ANIMAL OTHER IMAGING MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 16: GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET BY APPLICATIONS, 2013 2020 ($MILLION)
  • TABLE 17: GLOBAL SMALL ANIMAL MONITORING TREATMENT APPLICATION MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 18: GLOBAL SMALL ANIMAL BIODISTRIBUTION APPLICATION MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 19: PERKINELMER OPTICAL IMAGING REAGENTS FOR PRE CLINICAL IMAGING OF CANCERS
  • TABLE 20: GLOBAL SMALL ANIMAL CANCER CELL DETECTION APPLICATION MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 21: GLOBAL SMALL ANIMAL BIOMARKERS APPLICATION MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 22: ADVANTAGES AND LIMITATIONS OF IMAGING MODALITIES USED IN LONGITUDINAL STUDIES
  • TABLE 23: GLOBAL SMALL ANIMAL LONGITUDINAL STUDIES APPLICATION MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 24: GLOBAL SMALL ANIMAL EPIGENETICS APPLICATION MARKET BY GEOGRAPHY 2013 2020 ($MILLION)
  • TABLE 25: GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET REVENUE BY GEOGRAPHY, 2013 - 2020 ($MILLION)
  • TABLE 26: NORTH AMERICA SMALL ANIMAL IMAGING (IN VIVO) MARKET BY TECHNOLOGY, 2013 - 2020 ($MILLION)
  • TABLE 27: EUROPE SMALL ANIMAL IMAGING (IN VIVO) MARKET BY TECHNOLOGY, 2013 - 2020 ($MILLION)
  • TABLE 28: ASIA PACIFIC SMALL ANIMAL IMAGING (IN VIVO) MARKET BY TECHNOLOGY, 2013 - 2020 ($MILLION)
  • TABLE 29: LAMEA SMALL ANIMAL IMAGING (IN VIVO) MARKET BY TECHNOLOGY, 2013 - 2020 ($MILLION)
  • TABLE 30: THERMO FISHER SCIENTIFIC COMPANY SNAPSHOT
  • TABLE 31: THERMO FISHER OPERATING SEGMENTS
  • TABLE 32: SWOT ANALYSIS OF THERMO FISHER SCIENTIFIC
  • TABLE 33: SIEMENS AG. COMPANY SNAPSHOT
  • TABLE 34: SIEMENS AG OPERATING SEGMENTS
  • TABLE 35: SWOT ANALYSIS OF SIEMENS AG
  • TABLE 36: MEDISO MEDICAL IMAGING SYSTEMS COMPANY SNAPSHOT
  • TABLE 37: MEDISO MEDICAL IMAGING SYSTEMS OPERATING SEGMENTS
  • TABLE 38: SWOT ANALYSIS OF MEDISO MEDICAL IMAGING SYSTEMS.
  • TABLE 39: COMPANY SNAPSHOT LIFE TECHNOLOGIES CORPORATION COMPANY SNAPSHOT
  • TABLE 40: LIFE TECHNBOLOGIES CORPORATION OPERATING SEGMENTS
  • TABLE 41: SWOT ANALYSIS OF LIFE TECHNOLOGIES CORPORATION
  • TABLE 42: PROMEGA CORPORATION COMPANY SNAPSHOT
  • TABLE 43: PROMEGA CORPORATION OPERATING SEGMENTS
  • TABLE 44: SWOT ANALYSIS OF PROMEGA CORPORATION
  • TABLE 45: MILTENYI BIOTEC GMBH COMPANY SNAPSHOT
  • TABLE 46: MILTENYI BIOTEC GMBH OPERATING SEGMENTS
  • TABLE 47: SWOT ANALYSIS OF MILTENYI BIOTEC GMBH
  • TABLE 48: BRUKER CORPORATION COMPANY SNAPSHOT
  • TABLE 49: BRUKER CORPORATION OPERATING SEGMENTS
  • TABLE 50: SWOT ANALYSIS OF BRUKER CORPORATION
  • TABLE 51: FUJIFILM HOLDINGS CORPORATION COMPANY SNAPSHOT
  • TABLE 52: FUJIFILM HOLDING CORPORATION OPERATING SEGMENTS
  • TABLE 53: SWOT ANALYSIS OF FUJIFILM HOLDING CORPORATION
  • TABLE 54: PERKINELMER INC COMPANY SNAPSHOT
  • TABLE 55: PERKINELMER INC. OPERATING SEGMENTS
  • TABLE 56: SWOT ANALYSIS OF PERKINELMER INC
  • TABLE 57: ASPECT IMAGING LTD. SNAPSHOT
  • TABLE 58: ASPECT IMAGING LTD. OPERATING SEGMENTS
  • TABLE 59: SWOT ANALYSIS OF ASPECT IMAGING LTD.

List of Figures

  • FIG. 1: IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO (2020 2025)
  • FIG. 2: IMPACT ANALYSIS OF RAPID GROWTH SCENARIO (2020 2025)
  • FIG. 3: IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO (2020 2025)
  • FIG. 4: MULTIMODALITY IMAGING INSTRUMENTS
  • FIG. 5: TOP IMPACTING FACTORS FOR SMALL ANIMAL IMAGING (IN VIVO) MARKET
  • FIG. 6: TOP INVESTMENT POCKETS OF GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET
  • FIG. 7: TOP WINNING STRATEGIES IN GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET 2011-2014
  • FIG. 8: TOP WINNING STRATEGIES IN GLOBAL SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2011 2014
  • FIG. 9: PORTER'S FIVE FORCE MODEL OF BIO IMPLANTS MARKET
  • FIG. 10: VALUE CHAIN FOR SMALL ANIMAL IN VIVO IMAGING DEVICES
  • FIG. 11: PATENT ANALYSIS BY TYPE OF PATENTS (2012-2014)
  • FIG. 12: PATENT ANALYSIS BY GEOGRAPHY (2012-2014)
  • FIG. 13: MARKET PLAYER POSITIONING OF SMALL ANIMAL IMAGING (IN VIVO) MARKET, 2013 (MILLION)
  • FIG. 14: PHRMA MEMBER COMPANY R&D EXPENDITURES , 1995 2012 ($MILLION)
  • FIG. 15: GDP GROWTH (%) IN PHARMACEUTICAL AND RESEARCH ORGANIZATIONS, 2006 2050
  • FIG. 16: IN VIVO DETECTION OF RODENT BRAIN NEURO ARCHITECTURE USING MANGANESE ENHANCED MRI (MEMRI)
  • FIG. 17: HITACHI MICRO MRI IMAGING EQUIPMENT WITH MOSFET GATE
  • FIG. 18: BIODISTRIBUTION GRAPH DEPICTING THE DRUG/TARGET ENGAGEMENT OVER THE SEQUENTIAL TIMEFRAME
  • FIG. 19: IMAGING IN THE CANCER MANAGEMENT
  • FIG. 20: THERMO FISHER SCIENTIFIC REVENUE BY BUSINESS UNITS, 2013 ($MILLION)
  • FIG. 21: THERMO FISHER SCIENTIFIC REVENUE BY GEOGRAPHY (2013)
  • FIG. 22: SIEMENS AG REVENUE BY GEOGRAPHY (2013)
  • FIG. 23: LIFE TECHNOLOGIES CORPORATION REVENUE BY BUSINESS SEGMENT (2012)
  • FIG. 24: LIFE TECHNOLOGIES CORPORATION REVENUE BY GEOGRAPHY (2012)
  • FIG. 25: PROMEGA CORPORATION REVENUE GENERATED (2011 2013)
  • FIG. 26: BRUKER CORPORATION REVENUE BY BUSINESS SEGMENT (2013)
  • FIG. 27: BRUKER CORPORATION REVENUE BY GEOGRAPHY (2013)
  • FIG. 28: BRUKER CORPORATION REVENUE GENERATED ($MILLION) (2011 2013)
  • FIG. 29: FUJIFILM HOLDINGS CORPORATION REVENUE BY BUSINESS SEGMENTS (IMAGING) (2013)
  • FIG. 30: FUJIFILM HOLDING CORPORATION REVENUE GENERATED 2011 2013 (IMAGING SEGMENT, $MILLION)
  • FIG. 31: PERKINELMER INC REVENUE BY BUSINESS SEGMENTS 2013 (HUMAN HEALTH)
  • FIG. 32: PERKINELMER REVENUE BY GEOGRAPHY (2012)
Back to Top